Literature DB >> 9370946

Expression of vascular endothelial growth factor in lymphomas and Castleman's disease.

H D Foss1, I Araujo, G Demel, H Klotzbach, M Hummel, H Stein.   

Abstract

Vascular endothelial growth factor (VEGF) is one of the main angiogenic cytokines in human solid tumours and inhibition of VEGF-induced angiogenesis suppresses tumour growth. Some groups of malignant lymphoma, including peripheral T-cell lymphomas and Hodgkin's disease, are characterized by a conspicuous proliferation of small vessels. To test the hypothesis that VEGF may also be involved in the angiogenesis in lymphomas and other lesions of the lymphoid system, VEGF expression was analysed in tissues, employing in situ hybridization with a 35S-labelled RNA probe specific for this cytokine. Significant expression of VEGF transcripts was observed in Hodgkin's disease and peripheral T-cell lymphomas, particularly of the angioimmunoblastic type. In contrast, expression of this cytokine was minimal or absent in follicle centre lymphoma and chronic lymphocytic leukemia of B-cell type. VEGF was mainly observed in reactive non-lymphoid CD68-negative cells, which probably represent fibroblasts or myofibroblasts. In normal and ulcerated tonsils, VEGF was expressed in the squamous epithelium but only rarely found in the lymphoid tissue. Although infectious mononucleosis tonsils contained high numbers of VEGF-positive cells in the interfollicular zone, expression of this cytokine was not found in Epstein-Barr virus (EBV)-infected cells, as determined by simultaneous in situ hybridization for VEGF and EBV-encoded small nuclear RNAs (EBER). In 5/8 cases of Castleman's disease, germinal centres containing small vessels also showed expression of VEGF, in contrast to normal tonsillar germinal centres which are devoid of both vessels and VEGF transcripts. It is concluded that VEGF may be involved in the induction of the angiogenesis of both peripheral T-cell lymphomas and Hodgkin's disease, but not in low-grade B-cell lymphomas. In contradistinction to solid tumours, in which this cytokine is commonly secreted by the tumour cells themselves, in malignant lymphoma VEGF is not a product of neoplastic cells. Vascularization of germinal centres in Castleman's disease may also be a consequence of abnormal local expression of VEGF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370946     DOI: 10.1002/(SICI)1096-9896(199709)183:1<44::AID-PATH1103>3.0.CO;2-I

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  29 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  Incidental finding of Castleman's disease in an asymptomatic young adult.

Authors:  Ibrahim Shahbuddin; Damian McKeon
Journal:  BMJ Case Rep       Date:  2009-12-09

3.  Angiogenesis in nodal B cell lymphomas: a high throughput study.

Authors:  Alexandar Tzankov; Simone Heiss; Stephanie Ebner; William Sterlacci; Georg Schaefer; Florian Augustin; Michael Fiegl; Stephan Dirnhofer
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

4.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

Authors:  Alison T Stopeck; Joseph M Unger; Lisa M Rimsza; William T Bellamy; Maria Iannone; Daniel O Persky; Michael Leblanc; Richard I Fisher; Thomas P Miller
Journal:  Leuk Lymphoma       Date:  2009-05

5.  Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.

Authors:  Gregory K Hong; Pawan Kumar; Ling Wang; Blossom Damania; Margaret L Gulley; Henri-Jacques Delecluse; Peter J Polverini; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 6.  Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors:  Hazem E El-Osta; Razelle Kurzrock
Journal:  Oncologist       Date:  2011-03-25

7.  Castleman's disease in a patient with melanoma: the role of VEGF.

Authors:  Lokesh Shahani
Journal:  BMJ Case Rep       Date:  2012-04-28

8.  Haemangiopericytoma of the thyroid gland in combination with Hashimoto's disease.

Authors:  T Hansen; A Gaumann; M Ghalibafian; A Höferlin; A Heintz; C J Kirkpatrick
Journal:  Virchows Arch       Date:  2004-07-09       Impact factor: 4.064

Review 9.  The role of angiogenesis in human non-Hodgkin lymphomas.

Authors:  Domenico Ribatti; Beatrice Nico; Girolamo Ranieri; Giorgina Specchia; Angelo Vacca
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

Review 10.  Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma.

Authors:  J Ruan; K Hajjar; S Rafii; J P Leonard
Journal:  Ann Oncol       Date:  2008-12-16       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.